The stock price of BioAge Labs Inc (NASDAQ: BIOA) has surged by 3.20 when compared to previous closing price of 3.75, but the company has seen a 12.83% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-20 that Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended December 31, 2024.
Is It Worth Investing in BioAge Labs Inc (NASDAQ: BIOA) Right Now?
Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 1 as “sell.”
The public float for BIOA is 21.04M, and currently, short sellers hold a 8.49% ratio of that float. The average trading volume of BIOA on April 18, 2025 was 245.48K shares.
BIOA’s Market Performance
BIOA’s stock has seen a 12.83% increase for the week, with a -12.84% drop in the past month and a -23.21% fall in the past quarter. The volatility ratio for the week is 6.89%, and the volatility levels for the past 30 days are at 7.18% for BioAge Labs Inc The simple moving average for the last 20 days is 4.38% for BIOA stock, with a simple moving average of -63.55% for the last 200 days.
Analysts’ Opinion of BIOA
Morgan Stanley, on the other hand, stated in their research note that they expect to see BIOA reach a price target of $5, previously predicting the price at $40. The rating they have provided for BIOA stocks is “Underweight” according to the report published on December 10th, 2024.
Jefferies gave a rating of “Hold” to BIOA, setting the target price at $7 in the report published on December 09th of the previous year.
BIOA Trading at -6.17% from the 50-Day Moving Average
After a stumble in the market that brought BIOA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.46% of loss for the given period.
Volatility was left at 7.18%, however, over the last 30 days, the volatility rate increased by 6.89%, as shares sank -11.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.23% lower at present.
During the last 5 trading sessions, BIOA rose by +12.83%, in comparison to the 20-day moving average, which settled at $3.71. In addition, BioAge Labs Inc saw -33.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIOA starting from Barton Shane, who purchase 2,632 shares at the price of $18.00 back on Sep 27 ’24. After this action, Barton Shane now owns 2,632 shares of BioAge Labs Inc, valued at $47,376 using the latest closing price.
Pande Vijay Satyanand, the Director of BioAge Labs Inc, purchase 126,793 shares at $19.73 during a trade that took place back on Oct 01 ’24, which means that Pande Vijay Satyanand is holding 1,026,793 shares at $2,501,626 based on the most recent closing price.
Stock Fundamentals for BIOA
The total capital return value is set at -0.24.
Based on BioAge Labs Inc (BIOA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -5.92. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -33.04.
Currently, EBITDA for the company is -78.19 million with net debt to EBITDA at 5.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.86.
Conclusion
To put it simply, BioAge Labs Inc (BIOA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
